retatrutide phase 2 trial type 2 diabetes triple agonist glp-1 gip glucagon obesity Retatrutide, a GIP, and receptor Looking forward to when #retatrutide's

GHK-Cu and Infection-Related Readouts in Wound Contexts Mouse and clinical datasets point to a possible reduction in inflammatory proteases (for example, MMP-2/9) and cytokines (such as TNF-) in wounds exposed to GHK-Cu, aligning with lower observed infection rates in comparative ulcer care cohorts

NICE recommends considering this for people with a BMI 40 kg/m or 35 kg/m with comorbidities (with lower thresholds for people from certain ethnic groups), and for people with type 2 diabetes with a BMI between 30-34.9 kg/m

Additionally, BPC-157 has been shown to regulate inflammatory responses by reducing pro-inflammatory cytokines and stimulating the release of growth factors vital for healing

Chappell D, Hofmann-Kiefer K, Jacob M, Rehm M, Briegel J, Welsch U, Conzen P, Becker BF

it actually comes in a wide range of molecular weights (~50 - 2,000+ kDA) and size matters

The fluorescence signal intensity of GFP staining in different tissues (cecum, liver, heart, cortex, and hippocampus) was quantified starting from 20x magnification images of GFP-stained tissue slices